Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase

Trial Profile

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Tenecteplase (Primary) ; Alteplase
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms EXTEND-IA TNK
  • Most Recent Events

    • 28 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 26 Jan 2018 Primary endpoint (Proportion of patients with substantial angiographic reperfusion (mTICI) score of 2b/3 (restoration of blood flow to 50% of the affected arterial territory) or absence of retrievable thrombus at initial angiogram: non-inferiority and superiority of tenecteplase compared to alteplase) has been met, according to results presented at the International Stroke Conference 2018.
    • 26 Jan 2018 Results presented at the International Stroke Conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top